The Meals and Drug Administration (FDA) stated Tuesday in an announcement it has despatched warning letters to corporations promoting unapproved weight reduction medication.
The letter went to Xcel Peptides, Swisschems, Summit Analysis and Prime Peptides, 4 on-line corporations it stated have been promoting unapproved GLP-1 medication, together with semaglutide and tirzepatide. Semaglutide is thought for its use in Wegovy and Ozempic, whereas tirzepatide is present in Mounjaro and Zepbound.
Though the businesses placed on their web sites that the medication are solely supposed for analysis functions and never human use, the warning letters declare that “evidence obtained from your website establishes that your products are intended to be drugs for human use.”
The FDA additionally despatched an extra warning letter to Veronvy for sending unapproved and misbranded oral weight reduction medication that claimed to be FDA-approved.
The Hill has reached out to the named corporations for remark.
In keeping with the rules of the letters, the businesses have fifteen days to handle the issues and clarify their corrective procedures to the FDA. Failure to take action might lead to authorized motion together with, with out limitation, seizure and injunction, the FDA stated.
As weight reduction medication change into more and more fashionable, the FDA has repeatedly cracked down on regulating unapproved, misbranded and counterfeit variations of the medication. Final December, the FDA warned public customers about pretend Ozempic injections within the provide chain.
